trending Market Intelligence /marketintelligence/en/news-insights/trending/jluiwa3jo4a40c0pwoxd_g2 content esgSubNav
In This List

Insmed chairman steps down; replacement named

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Insmed chairman steps down; replacement named

Insmed Inc. said Donald Hayden Jr. stepped down as the company's chairman.

Hayden has been Insmed's board chairman since December 2010. He will remain a member of the board, Insmed said.

The company appointed President and CEO Will Lewis to replace Hayden as chairman.

Myrtle Potter also retired as a director due to the demands of her role as vant operating chair of Roivant Pharma, a Roivant Sciences Ltd. unit.

The company appointed Elizabeth Anderson to replace Potter's board seat. Anderson was formerly with Janssen Pharmaceuticals as the worldwide vice president for infectious disease and vaccines.

Janssen Pharmaceuticals is a Johnson & Johnson unit.

Additionally, David Brennan was elected as lead independent director of Insmed. Brennan became an Insmed director in May 2014.

Bridgewater, N.J.-based Insmed is a global biopharmaceutical company focused on developing treatment options for patients with serious and rare diseases.